Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Karanth SS, Lairson DR, Savas LS, Vernon SW, Fernandez ME. The cost of developing a computerized tailored interactive multimedia intervention vs. a print based photonovella intervention for HPV vaccine education. Eval Program Plann. 2017 Aug;63:1-6. doi: 10.1016/j.evalprogplan.2017.02.009
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
French MT, Bradley CJ, Calingaert B, Dennis ML, Karuntzos GT. Cost analysis of training and employment services in methadone treatment. Eval Program Plann. 1994 Apr 1;17(2):107-20.